Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Supports reduction of dark spots and uneven tone
For patients who may find injectable therapies challenging or undesirable, an oral alternative may improve both initiation and continuation of therapy. Rothberg, who was likewise not involved with the new trial, hopes Lilly will pass on cost savings to patients if the drug is approved
Market Opportunities Biosimilar Liraglutide Access Markets, Emerging Geography Expansion, and Precision Obesity Medicine Unlock Underserved GLP-1 Market Growth Segments Biosimilar liraglutide entry represents the first generic competition wave for the GLP-1 weight loss drug category, expanding access for the 480 million obesity patients in lower-middle income countries for whom USD 1,000-plus monthly branded drug pricing is permanently inaccessible
Roediger 1998
US$ 26.30
.jpg)
US$ 29.30
US$ 24.46
US$ 20.28
US$ 24.86
US$ 28.23
US$ 20.16
US$ 29.12
